U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07310186) titled 'Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy' on July 22.
Brief Summary: Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great ...